Endothelin receptor blockade reduces ventricular dysfunction and injury after reoxygenation

Area of Science:

• Cardiovascular Research
• Neonatal Cardiology
• Pharmacology

Background:

• Reoxygenation after hypoxia impairs ventricular function and causes cellular injury in congenital heart defect repair.
• Endothelin-1 (ET-1), elevated during hypoxia, may worsen myocardial function and activate leukocytes.
• Investigating endothelin receptor antagonists could mitigate post-hypoxic reoxygenation injury.

Purpose of the Study:

• To evaluate the efficacy of an endothelin receptor antagonist in improving ventricular function and reducing cardiac injury following hypoxia and reoxygenation.
• To assess the impact of ET-1 receptor blockade on myocardial function and cellular damage in a neonatal model.

Main Methods:

• Piglets underwent 90 minutes of hypoxia, followed by 1 hour of reoxygenation on cardiopulmonary bypass.
• One group received Bosentan (ET(A/B) receptor antagonist) infusion during hypoxia and reoxygenation; a control group did not.
• Ventricular function (dP/dt), ET-1 and iNOS mRNA levels, myeloperoxidase activity, lipid peroxidation, and apoptotic index were measured.

Main Results:

• Bosentan preserved right and left ventricular dP/dt, unlike controls which showed significant decreases.
• The antagonist reduced ET-1 and iNOS mRNA expression, myeloperoxidase activity, and lipid peroxidation.
• Bosentan treatment led to a lower myocardial apoptotic index compared to controls.

Conclusions:

• Endothelin-1 receptor antagonism significantly improved functional recovery and reduced leukocyte-mediated injury post-reoxygenation.
• Blocking ET-1 receptors decreased cardiac cell death, potentially improving long-term outcomes after reoxygenation injury.